Clay Siegall is a successful man who has helped in changing the world. He has a B.S in Zoology from the University of Maryland and a Ph.D in genetics from George Washington University. He is the CEO, co-founder and president of Seattle Genetic as well a member of the board of the company where he serves as the chairman. He is a professional entrepreneur and scientist. Siegall is a man devoted to his work and as a result he has been awarded by Maryland University as the 2013 Alumnus for computer, natural sciences and math. He has so much experience in the biotechnology industry.
Biotechnology is grouping a collection of microorganisms so that a certain drug can be created through the manufacturer of these microorganisms. The end goal of creating these drugs is to find a better treatment of cancer. Seattle Genetics is working towards this project to initiate a good antibody drug conjugate (ADC). The patients suffering from cancer are hopeful because Siegall and his team are putting an effort to find the best solution to treat cancer. They have so far achieved in making the first drug called Adcetric which in a short period has spread in over 60 countries globally.
Seattle Genetics’s financial graph has massively improved over the years because of the hard work of the people at the company. More than 20 ADCs of the company have been supplied in different clinical developments. Clay Siegall has worked hard due to his experience to make the achievement. $330 million is the sum of money that the firm has achieved since it began. The organization is devoted to assisting patients suffering from cancer, for instance more than 15,000 patients of Lymphoma all over the world have received Adcetris.
Cancers like acute myeloid have gotten SGN-CD33A which has also been created by the company and SGN-CD19A in non-Hodgkin lymphoma. As a result the treatment results are progressing well. The organization gives hope to the patients by telling them that they are working on better cancer therapies by for instance associating with related firms to have the best therapies to treat cancer.